ArticleTranslational cancer research2019
Prostate health index is useful for prostate cancer detecting in Chinese people.
Article in Translational cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Development and validation of a prostate cancer risk prediction model for the elevated PSA population.Frontiers in oncology · 2025Article
- Comprehensive analysis of alternative splicing profiling reveals novel events associated with prognosis and the infiltration of immune cells in prostate cancer.Translational andrology and urology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (PCa) incidence was increased substantially in the last two decades in China. We evaluated the performance of prostate health index (PHI) in predicting the presence of PCa in Chinese people.
methodsA total of 108 consecutive patients were recruited to develop a PHI-based nomogram to predict PCa. Serum total prostate specific antigen (tPSA), free PSA (fPSA), and p2PSA were measured by Beckman Coulter's DxI 800 Immunoassay System. PHI was calculated by [p2PSA/fPSA]×. Performance of individual PSA and PHI measurements in discriminating clinical outcomes was measured using the detection rate of PCa, sensitivity, specificity, and area under the receiver operating characteristic curve (AUC).
resultsAmong all patients, PHI was a better predictor of PCa compared with tPSA. PHI achieved the highest AUC of 76.6% in discriminating PCa from non-PCa compare to tPSA measurement, the difference of AUC area between PHI and PSA was about 6% in the entire cohort. The PHI-based nomogram reduced the number of biopsies. With the cutoff value (tPSA >4 ng/mL, PHI >40), there were 37 patients need to do biopsies in tPSA >4 ng/mL group, while with PHI >40, only 30 patients need to do. Seven patients could avoid unnecessary biopsies. When combined with the two values (tPSA >4 ng/mL, PHI >40) only 24 patients remained.
conclusionsOur finding has implication PHI and provides added value over tPSA for PCa detecting in Chinese people.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.